about
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach.Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study.Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Effects of cannabis use on age at onset in schizophrenia and bipolar disorder.Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysisPrevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.The management of schizophrenia: focus on extended-release quetiapine fumarate.Introduction to sertindole in clinical practice.Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaClinical effectiveness in adults with chronic schizophrenia.Electroconvulsive therapy in Belgium: a questionnaire study on the practice of electroconvulsive therapy in Flanders and the Brussels Capital region.Treatment of cognitive dysfunction in schizophrenia.Anticonvulsants during electroconvulsive therapy: review and recommendations.A case series: evaluation of the metabolic safety of aripiprazoleTypical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program.Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia.Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review.Management of acutely ill patients in the hospital setting: focus on quetiapine.Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.Predictors of patient satisfaction after ultrabrief bifrontal and unilateral electroconvulsive therapies for major depression.Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.A head-to-head comparison of sertindole and risperidone on metabolic parameters.MTHFR and risk of metabolic syndrome in patients with schizophrenia.MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study.Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).Concurrent use of lamotrigine and electroconvulsive therapy.A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.Knowledge about HIV in people with schizophrenia: a general population comparison.Treatment of depression in first episode of schizophrenia: results from EUFEST.Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder.Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission iA double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
P50
Q33185340-806F620F-C322-48B2-916C-558DC516ADE0Q33515513-4F005325-D1AF-4018-8DC5-34A134F460EBQ33538984-0B7ED7A1-91B3-4868-AF3A-69E3FAA6A73EQ33814003-6B6FF9F8-066C-4CE1-BEA5-DF9085442BF2Q33862078-D77BEEE4-DAF5-472F-A607-00D68B800686Q34128935-51DB9CC7-2CED-483B-8AB8-A1177B04F7B9Q34398243-E33F4F13-9208-4D65-998D-11FD2CD0D2FFQ34708413-B67B9FAB-582E-4859-ADED-C1F02A7F5610Q35327044-7A6A6908-54C3-4446-BC3A-F9BCB2D29DFDQ35906811-F491D1EF-590B-4767-9E8E-BC3D1781E7F9Q35948848-06C49546-6589-472A-82A3-DD54F9BB99B8Q35968022-EB559773-4EC6-4087-8B88-0DE82F2632C4Q36080418-EFDE1433-F6FD-4F16-913E-B401F9E03847Q36273876-2C204FAC-F5CC-48BB-BB28-D1D0F4B60E44Q36840552-79746166-93F3-4363-BB57-222B13084698Q36853249-27E62E54-8B9D-4A34-BB63-FCE7129F2EA9Q37094404-CD51A68D-0175-48B6-B66B-302DD8AAF751Q37235620-00DA8612-EB10-46E9-ADF4-AAB7A167DE16Q37714573-12FC1359-D0E2-48B7-ABEE-8B7C118207F0Q37734656-AA178E83-F153-4DCF-8346-BCE130616CD5Q38201749-EF8348C4-879A-4E39-B9BF-C436AE15D7FAQ38221210-EFB8E2BB-F711-4045-8DCB-8BB9DC900E17Q38463550-95C392F1-33DF-420A-BA3A-912FCD3CBA7EQ38570636-7146EA8B-7FD8-433B-B25D-F671C241D2CBQ39977924-00478125-DBF7-4FB9-AE7E-C152993CE7A5Q42626345-54E164B3-5444-4C08-AC20-8F0F3DD6B13FQ42704612-63A27A35-F3F1-4A85-838D-EC4ACC9F1504Q42928643-941E3518-B466-454D-8497-A4C72B568C80Q43023811-185B1072-4F39-46D4-9623-9164CB25D2F0Q43044728-088FD5CF-319D-4566-82D1-5D6DCB3B6DC8Q43264112-FD8C99CC-4BBD-4379-9303-6DC8DF3D521AQ44013506-FF46D469-C60E-4571-9F39-D44FC5062359Q44223204-3EA60D73-2698-422B-8EEE-238FF528E343Q44387137-CB29C521-CFE0-43F8-9DBC-33310B7DDACAQ44625111-1B08D37C-7926-4018-8F51-9729404BDD08Q44804106-98187AA4-81C3-403D-8A03-A8067027953AQ44830864-D7DA988C-B380-40E7-AF4A-8F988C149D6EQ44838692-6C2B0FED-0D41-4DE0-8350-85732E8E14E1Q44966962-ADF15DF8-4655-4CAE-9864-FDA29C90C6D0Q45396061-79119B16-F661-4113-AE03-67F9DF06CA03
P50
name
Joseph Peuskens
@ast
Joseph Peuskens
@en
Joseph Peuskens
@es
Joseph Peuskens
@nl
type
label
Joseph Peuskens
@ast
Joseph Peuskens
@en
Joseph Peuskens
@es
Joseph Peuskens
@nl
prefLabel
Joseph Peuskens
@ast
Joseph Peuskens
@en
Joseph Peuskens
@es
Joseph Peuskens
@nl